A5048115856- Myasthenia Gravis and Thymoma
- Liver Disease and Transplantation
- Peripheral Neuropathies and Disorders
- Ethics in Clinical Research
- Health Systems, Economic Evaluations, Quality of Life
- Liver Disease Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Ethics in medical practice
- Pharmaceutical Practices and Patient Outcomes
- Asthma and respiratory diseases
- Organ Transplantation Techniques and Outcomes
- Biomedical Ethics and Regulation
- Cystic Fibrosis Research Advances
- Parkinson's Disease and Spinal Disorders
- Surgical site infection prevention
- Pleural and Pulmonary Diseases
- Healthcare Systems and Challenges
- Regulation of Appetite and Obesity
- Thyroid and Parathyroid Surgery
- Gout, Hyperuricemia, Uric Acid
- Bipolar Disorder and Treatment
- Healthcare Systems and Technology
- Potassium and Related Disorders
- Drug-Induced Hepatotoxicity and Protection
Vall d'Hebron Hospital Universitari
2003-2023
Vall d'Hebron Institut de Recerca
2019
Universitat Autònoma de Barcelona
2012-2015
Hebron University
2010
American Pharmacists Association
2004
Publication bias may affect the validity of evidence based medical decisions. The aim this study is to assess whether research outcomes dissemination clinical trial findings, in terms rate, time publication, and impact factor journal publications.All drug-evaluating trials submitted approved by a general hospital ethics committee between 1997 2004 were prospectively followed analyze their fate publication. Published articles identified searching Pubmed other electronic databases. Clinical...
BACKGROUND: Non—cystic fibrosis (CF) patients with bronchiectasis usually develop chronic bronchial infection Pseudomonas aeruginosa (PA) that is related to worsening lung function and increased morbidity mortality. OBJECTIVE: To determine whether direct aerosol delivery of tobramycin the lower airways may control produce only low systemic toxicity. METHODS: A double-blind, placebo-controlled crossover trial involving 30 was conducted clinical effectiveness safety 6-month inhalation therapy....
Objective: To assess the transthyretin (TTR) stabilization activity of tolcapone (SOM0226) in patients with hereditary ATTR amyloidosis, asymptomatic carriers and healthy volunteers.Methods: A phase IIa proof-of-concept trial included two phases separated by a 6-week washout period. Phase A: single 200 mg dose tolcapone; B: three 100 doses taken at 4 h intervals. The primary efficacy variable was TTR stabilization.Results: Seventeen subjects were (wild type, n = 6; mutation Val30Met, 11)....
Confirm in patients with cirrhosis and gastrointestinal bleeding the safety of ornithine phenylacetate (OP) assess pharmacokinetic profile OP its effects on plasma ammonia.OP is a drug that has shown experimentally to decrease hyperammonemia improve hepatic encephalopathy. safe healthy subjects stable cirrhosis, but there are no data decompensated cirrhosis.We performed study tolerance cirrhotic after an episode upper bleeding.Ten were included within 24 hours bleeding. was administered as...
Background: Ornithine phenylacetate (OP) has been proven effective in lowering ammonia plasma levels animals, and to be well tolerated cirrhotic patients. A trial assess OP efficacy versus placebo patients after an upper gastrointestinal bleeding was performed. The primary outcome a decrease venous at 24 hours. Methods: total of 38 consecutive were enrolled within hours bleed. Patients randomized (1:1) receive (10 g/day) or glucosaline for 5 days. Results: not achieved. progressive observed...
Background: In the phase III eculizumab for refractory generalized myasthenia gravis REGAIN study [ClinicalTrials.gov identifier: NCT01997229] and its open-label extension (OLE) NCT02301624], patients with treatment-refractory antiacetylcholine receptor antibody-positive had clinically meaningful improvements versus placebo. This subgroup analysis evaluated data from a recent history of chronic intravenous immunoglobulin (IVIg) use before entry. Methods: The comprised who received IVIg at...
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are renoprotective but both may increase serum potassium concentrations in patients with chronic kidney disease (CKD). The proportion of affected patients, the optimum follow-up period whether there differences between drugs development this complication remain to be ascertained. In a randomized, double-blind, phase IV, controlled, crossover study we recruited 30 stage 3 CKD under restrictive eligibility criteria...
Background: Myasthenic crisis (MC) is a potentially life-threatening complication of myasthenia gravis. Its precipitating factors include surgical procedures, particularly thymectomy. The role preoperative intravenous immunoglobulin (IVIg) in preventing MC patients scheduled for thymectomy and other surgery with general anaesthesia unknown. Our objective was to test the hypothesis that IVIg effective myasthenic gravis under anaesthesia, including Methods: A prospective, randomized,...
<h3>Background</h3> Long-term anticoagulation is widely used for secondary thromboprophylaxis in the antiphospholipid syndrome (APS) due to high risk of recurrent events. Currently with vitamin K antagonists (VKAs) standard care but have unpredictable pharmacodynamic properties that requiere monitoring dose adjustment. Rivaroxaban, an orally active direct factor Xa inhibitor, has been shown be effective and safe compared warfarin treatment venous thromboembolism non valvular atrial...
May 7, 2019April 9, 2019Free AccessIntravenous Immunoglobulin to prevent Myasthenic Crisis after Thymectomy and other Surgical Procedures can be omitted: A Randomized, Controlled, Double-Blind Trial. (Plen02.003)Josep Gamez, Maria Salvado, Francesc Carmona, Miriam de Nadal, Daniel Ruiz, Olga Martinez, Deu, Pilar Suñe, Laura Romero, Alberto Jáuregui, Javier PérezAuthors Info & AffiliationsApril 2019 issue92 (15_supplement)https://doi.org/10.1212/WNL.92.15_supplement.Plen02.003 Letters the Editor